Clinical trials: Levodopa
Retinal Diseases
Effect of Levodopa on Human Multifocal Electroretinogram
It is known that dopamine is a functional neuromodulator at several levels of the visual system. Dopamine seems to be involved in the organization of the ganglion cell and the bipolar cell receptive fields and modulation of…
- Trial name
- NCT00812760
- Testing
- levodopa
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Dopamine Activity, Episodic Memory Consolidation
Dopaminergic Modulation of Cognition and Psychomotor Function
A recent study at our lab showed increased episodic memory consolidation and response readiness after treatment with methylphenidate in healthy volunteers. The investigators seek to replicate and extend these findings.
- Conditions
- Dopamine Activity, Episodic Memory Consolidation, Response Preparation
- Trial name
- NCT01218425
- Testing
- Methylphenidate 40 mg, Levodopa/carbidopa 125 mg, Domperidon 10 mg
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Parkinson's Disease
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
The purpose of this clinical research study is to determine if different dosage regimens of Sinemet® CR (Carbidopa/levodopa) are dose proportional
- Trial name
- NCT00460954
- Testing
- Sinemet® controlled release (Carbidopa/levodopa)
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Parkinson's Disease
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus
Parkinson'disease is a neurodegenerative disorder characterised by bradykinesia, rigidity, rest tremor and postural instability.
- Trial name
- NCT00664157
- Testing
- Facial expression recognition of emotion
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease (PD), Periodontitis
Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's Disease
The aim of this study is to evaluate the effects of Levodopa-Benserazide drug combination on periodontal status and salivary cytokine levels in patients with Parkinson's disease.
- Conditions
- Parkinson Disease (PD), Periodontitis, Periodontal Diseases
- Trial name
- NCT07405268
- Where
- Turkey (Türkiye)
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Parkinson Disease
Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of rising oral single-doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of immediate release levodopa/carbidopa 100/25…
- Trial name
- NCT03091868
- Testing
- Sinemet® 100/25, Comtan®, BIA 6-512 25 mg
- Where
- Portugal
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Pharmacokinetic Study in Healthy Males
The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.
- Trial name
- NOCOF (NCT02312232)
- Testing
- levodopa, carbidopa, ODM-104
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Haloperidol, Placebo
Pharmacological Modulation of Belief Salience
To provide an initial test of the hypothesis that dopamine mediates the motivational salience of stimuli beyond simple stimulus-reinforcement associations, the researchers propose to undertake a study of the modulation of a)…
- Conditions
- Haloperidol, Placebo, L-DOPA
- Trial name
- MOBS (NCT03754062)
- Testing
- L-dopa, Haloperidol
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- King's College London
Fasted State
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by means two fixed combination products (test…
- Trial name
- LCD18K (NCT02116465)
- Testing
- Levodopa Carbidopa immediate release tablets
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
The purpose of this study was to determine whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose of…
- Trial name
- NCT03097211
- Testing
- BIA 6-512, Madopar® 250, Nebicapone
- Where
- Portugal
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease (PD)
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a…
- Trial name
- NCT02169414
- Testing
- BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Volunteers
Dose-finding Pharmacokinetic Study in Healthy Males
This is a phase I PK study in healthy males.
- Trial name
- COMDOS1 (NCT03055936)
- Testing
- Levodopa, Carbidopa, ODM-104
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1.
- Trial name
- NCT01486628
- Testing
- ND0612
- Where
- Israel
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
Levodopa Concentration Profile With Stalevo 75/125 mg
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.
- Trial name
- NEWSTA (NCT01070628)
- Testing
- Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Healthy Volunteers
Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers
A group of 24 healthy volunteers receive one tablet of an association of levodopa 200 mg and benserazide 50 mg corresponding to two drug products: a test formulation (Evoser ®; Phoenix S.A.I.C.
- Trial name
- PHOE10903 (NCT01327261)
- Testing
- Levodopa + benserazide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires
Parkinson´s Disease
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
The aims of this proposal include tests of hypotheses of the pathogenetic mechanisms of noradrenergic neurotransmission in Parkinson's disease in vivo, using positron emission tomography of patients with early and advanced…
- Trial name
- NORAPARK (NCT02578849)
- Testing
- L-DOPA
- Where
- Denmark
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169479
- Testing
- BIA 9-1067, Sinemet® 100/25
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach
- Trial name
- NCT02486432
- Testing
- Levodopa/Carbidopa (Sinemet)
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.